Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis

BACKGROUND: Pathogenic variants (PVs) in BRCA1/2 genes account for ∼6% of breast and 20% of ovarian cancers. Most breast tumors developed by BRCA1 carriers are triple negative. BRCA2 tumors have similar rates of estrogen receptor positivity as sporadic controls but are less likely to be human epider...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomasello, G., Gambini, D., Petrelli, F., Azzollini, J., Arcanà, C., Ghidini, M., Peissel, B., Manoukian, S., Garrone, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463372/
https://www.ncbi.nlm.nih.gov/pubmed/35810556
http://dx.doi.org/10.1016/j.esmoop.2022.100531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463372/
https://www.ncbi.nlm.nih.gov/pubmed/35810556
http://dx.doi.org/10.1016/j.esmoop.2022.100531

Ejemplares similares